TRACON Pharmaceuticals (NASDAQ:TCON) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research report issued on Saturday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Price Performance

TCON opened at $0.03 on Friday. The business has a fifty day simple moving average of $0.06 and a 200 day simple moving average of $0.43. TRACON Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $14.75. The company has a market capitalization of $109,802.00, a PE ratio of 0.01 and a beta of 1.37.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.